medigraphic.com
ISSN 2992-8036 (Digital)
ISSN 2306-4102 (Impreso)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2001, Número 2

<< Anterior Siguiente >>

Acta Ortop Mex 2001; 15 (2)


Eficacia del tratamiento farmacológico de la osteoporosis en la prevención de fracturas

Gómez-García F

Idioma: Español
Referencias bibliográficas: 169
Paginas: 70-85
Archivo PDF: 101.88 Kb.


RESUMEN

En el presente artículo se hace una exhaustiva revisión bibliográfica de las investigaciones y resultados clínicos de las drogas más utilizadas para el tratamiento de la osteoporosis, así como de la efectividad de cada una de ellas para prevenir una fractura. También se discuten los problemas más importantes para prevenir, diagnosticar y tratar esta enfermedad con un costo-beneficio razonable. Al final se discuten algunas estrategias y sugerencias para definir si es necesaria o no una intervención farmacológica, y si ésta se considera necesaria, de qué tipo debe ser.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aguado P, Garces MV, Gonzalez ML, Del Campo MT, Martinez ME: Relationship between calcidiol serum levels and bone mineral density in post-menopausal women. Calcif Tissue Int 1995; 64: S75.

  2. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T: Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol 1999; 93: 258-64.

  3. Ames SK, Ellis KJ, Gunn SK, Copeland KC, Abrams SA: Vitamin D receptor gene Fok 1 polymorphism predicts calcium absorption and bone mineral density in children. J Bone Miner Res 1999; 14: 740-6.

  4. Balena R, Kleerekoper M, Foides JA, Shih M-S, Rao SD, Schober HC, Parfitt AM: Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodeling and mineralization of bone. Osteop Int 1998; 8: 428-35.

  5. Ballard-Barbash R, Forman MR, Kipnis V: Dietary fat, serum estrogen levels, and breast cancer risk: a multi-faceted story. J Natl Cancer Inst 1999; 91: 492-4.

  6. Beardsworth SA, Kearney CE, Steel SA, Purdie DW: A five year prospective study of BMD and fracture risk in HRT treated and untreated peri-menopausal women. Calcif Tissue Int 1999; 64 (Suppl 1): S43.

  7. Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Fauser BCJM: Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with tibolone. Maturitas 1999; 31: 151-9.

  8. Bettica P, Bevilacqua M, Vago T, Norbiato G: High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteopor Int 1999; 9: 226-9.

  9. Biank MA, Ems BL, Gibson GW, Myers WR, Berman SK, Phipps RJ, Smith PN: Nonclinical model for assessing gastric effects of bisphosphonates. Digest Dis Sci 1997; 42: 281-8.

  10. Bischoff H, Stahelin BB, Vogt P, Friderich P, Vonthein R, Tyndall A, Thelier R: Immobility as a major cause of bone remodeling in residents of along-stay geriatric ward. Calcif Tissue Int 1999; 64: 485-9.

  11. Black DM, et al: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.

  12. Black DM, Thompson DE, Bauer D, Hochberg M, Ensrud K, Musiiner TA, Yates AI, Cummings SR: Antifracture efficacy of alendronate in patients at high risk of fracture: Results from the fracture intervention trial. Calcif Tissue Int 1999; 64(Suppl 1): S78.

  13. Boivin G, Meunier PJ: Bone remodeling changes influence the mean degree of mineralization of bone tissue. Therapeutic implications. Calcif Tissue Int 1999; 64: S78.

  14. Bots ML, Launer LL, Lindemans J, Hoes AW, Hofman A, Witteman JCM, Koudstaal PJ, Grobbee DE: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. Arch Intern Med 1999; 159: 38-44.

  15. Brago A, Hannon R, Easteli R: Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999; 4: 602-8.

  16. Cardona JM, Pastor E: Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. Osteopor Int 1998; 7: 165-74.

  17. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999; 130: 270-7.

  18. Cepollaro C, Gonnelli S, Pondrelli C, Martini S, Montagnini A, Rossi B, Gennari C: Usefulness of ultrasound in Sudeck’s atrophy of the foot. Calcif Tissue Int 1998; 62: 538-41.

  19. Chesnut Ch, Silverman S, Andriano K, et al: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. JAMA 2000; 109: 267-76.

  20. Cocquyt V, et al: Pharmacokinetics of intravenous alendronate. J Clin Pharmacol 1999; 39: 385-93.

  21. Compston JE: Vitamin D deficiency: Time for action. Br Med J 1998; 317: 1466-7.

  22. Compston JE, Papapoulos SE, Blanchard F: Report on osteoporosis in the European Community: Current status and recommendations for the future. Osteopor Int 1998; 8: 531-4.

  23. Cummings SR: Prevention of hip fractures in older women. A population based perspective. Osteop Int Suppl 1998; I: S8-S12.

  24. Cummings SR, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280: 2077-82.

  25. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B: Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733-8.

  26. Davies GC, Huster WJ, Lu, Plouffe L, Lakshmanan M: Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-65.

  27. Davis SR: Androgen replacement in women: A commentary. J Clin Endocrinol Metab 1999; 84: 1886-91.

  28. Davis SR, Burger HG: The rationale for physiological testosterone replacement in women. Clin Endocrinol Metab 1998; 12: 391-404.

  29. De Leo V, la Marca A, Morgante G, Lanzetta D: Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas 1999; 31: 171-7.

  30. Delmas PD, et al: Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Calcif Tissue Int 1999; 64: S43.

  31. Delmas PD, Pornel G, Feselbergh D, Garnero P, Hardy P, Pilate C, Dain M-P: A dose-ranging trial of a matrix transdermal 17 beta-estradiol for the prevention of bone loss in early postmenopausal women. Bone 1999; 4: 517-23.

  32. Diamond T, Smerdely P, Kormas N, Sekel R, Vu T, Day P: Hip fracture in elderly men: The importance of sub-clinical vitamin D deficiency and hypogonadism. Med J Aust 1998; 169: 138-41.

  33. Douchi T, Yamamoto S, Nakamura S, Oki T, Maruta K, Nagata Y: Bone mineral density in postmenopausal women with endometrial cancer. Maturitas 1999; 31: 165-170.

  34. Dooley M, Balfour JA: Ibandronate. Drugs 1999; 57: 100-8.

  35. Downs RW, Bone HG, McIlwain H, Baker MZ, Yates AJ, Lombardi A, Krupa D, Harning: An open-label extension study of alendronate treatment in elderly women with osteoporosis. Calcif Tissue Int 1999; 64: 463-9.

  36. Easteli R, Minne H, Sorensen O, Hooper M, Ritter-Hrncrick C, Pack S, Roumagnac I, Ethgen D, Reinster JY: Risedronate reduces fracture risk in women with established postmenopausal osteoporosis. Calcif Tissue Int 1999; 64(Suppl 1): S43.

  37. Eddy DM, Johnston CC, Cummings SR, Dawson-Hughes B, Lindsay R, Meltron LS, Slemenda ChW: Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis: Status report. Osteoporos Int 1998; (Suppl. 4): S1-S88.

  38. Eddy MD, Johnston Jr. CC, Cummings SR, Dawson-Hughes B, et al: Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporosis Int 1988; 4(Suppl).

  39. El-Hajj Fuieihan G, Deeb M: Hypovitaminosis D in a sunny country. N Engl Med 1999; 340: 1840-1.

  40. Ensrud K, Seeley D, Nguyen T, White C, Lipschutz R, Zmuda J, Cauley I, Eisman J, Cummings S: Vitamin D receptor (VDR) genotype and fracture risk in older women: The Study of Osteoporotic Fractures. J Bone Miner Res 1997; 12(Suppl 1): S127.

  41. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB: Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med 1997; 157: 2617-24.

  42. Erben RG, Bromm S, Stangassinger M: Therapeutic efficacy of la 25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: Evidence for a direct anabolic effect of la, 25-dihydroxyvitamin D3, on bone. Endocrinology 1999; 139: 4319-28.

  43. Eriksen EF, Meisen F, Brown JP, Sacco-Gibson N, Balena R, Sod EW, Axelrod DW, Chines A: Histology and histomorphometry in post-menopausal osteoporotic women receiving three years of risedronate treatment. Calcif Tissue Int 1999; 64(Suppl 1): S69.

  44. Ettinger B, Pressman A, Schein J: Clinical visits and hospital admissions for care of acid related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J of Man C 1998; 4(10): 1377-82.

  45. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N: Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J of Mang Care Pharm 1998; 4(5): Sep/oct.

  46. Feisenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W: Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. Maturitas 1988; 31: 35-43.

  47. Ferrari S, Manen D, Bonjour J-P, Siosman D, Rizzoli R: Bone mineral mass and calcium and phosphate metabolism in young men: Relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 1999; 84: 2043-8.

  48. Feskanich D, Hunter DI, Willett WC, Hankinson SE, Hollis BW, Hough HL, Kelsey KT, Coiditz GA: Vitamin D receptor genotype and the risk of bone fractures in women. Epidemiology 1998; 9: 535-9.

  49. Fitzpatrick LA: Selective estrogen receptor modulators and phytoestrogens: New therapies for the post-menopausal women. Mayo Clin Proc 1999; 74: 601-7.

  50. Fogelman I, Ribot C, Smith R, Bettica P, Pacak S, Ethgen D, Reginster JY: Risedronate produces dose-dependent increases in bone mineral density in post-menopausal women with low bone mass. Calcif Tissue Int 1999; 64(Suppl 1): S69.

  51. Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS: Calciotrophic hormones and bone markers in the elderly. J Bone Miner Res 1998; 13: 475-82.

  52. Gapstur SM, Morrow M, Sellers TA: Hormone replacement therapy and risk of breast cancer with a favorable history. Results of the Iowa Women’s Health Study. JAMA 1999; 281: 2091-7.

  53. George GEM, MacGregor AI, Spector TD: Influence of current and past hormone replacement therapy on bone mineral density: A study of discordant postmenopausal twins. Osteoporos Int 1999; 9: 158-62.

  54. Geusens P, Vanhoof J, Declerck K, Bruckers L, Molenbergs G, Raus J: Effect of vitamin D supplements on bone density and muscles strength in elderly women. A double-blind, placebo-controlled study. Calcif Tissue Int 1999; 64: S44.

  55. Giorgino R: Ultrasonometry in monitoring treatment. Presented at the second joint meeting of ASBMWIBMS, San Francisco, CA, December, 1998.

  56. Giorgino R, Paparella P, Lorusso D, Mancuso S: Longitudinal effects of three-year hormonal replacement therapy on quantitative ultrasound bone measurements. J Bone Miner Res 1997; 12(Suppl 1): S103.

  57. Glerup H, Eriksen EF, Langdahl B: Vitamin D receptor polymorphisms predict the severity and response to treatment in vitamin D deficiency myopathy. Calcif Tissue Int 1999; 64(Suppl 1): S39.

  58. Glerup H, Garden M, Jensen J, Eriksen EF: Vitamin D deficiency among hip fracture patients: Severe myopathy precedes bone involvement. Osteopor Int 1998; 8(Suppl): 103.

  59. Goa KL, Balfour JA: Risedronate. Drugs Aging 1998; 13: 83-91.

  60. Gonnelti S, Cepollaro C, Montomoli M, Gennari L, Montagnini A, Palmieri R, Gennari C: Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: A placebo controlled study. Clin Endocrinol 1997; 46: 55-61.

  61. Goodman SN: Toward evidence based medical statistics. 2: the Bayes factor. Ann Intern Med 1999; 130: 1005-13.

  62. Graafmans WC, Lips P, Ooms ME, van Leeuwen JPTM, Pois HAP, Uitterlinden AG: The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997; 12: 1241-5.

  63. Greendale GA, Reboussin BA, Sie A, Singh R, Oison LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999; 130: 262-9.

  64. Grodstein F, Newcomb PA, Stampfer MI: Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-82.

  65. Grodstein F, Stampfer MJ: Estrogen for women at varying risk of coronary disease. Maturitas 1998; 30: 19-26.

  66. Guyatt GH: Evidence-based management of patients with osteoporosis. J Clin Densitometry 1998; 1: 395-402.

  67. Haden ST, Fuleihan GEH, Angell JE, Cotran NM, LeBoff MS: Calcidiol and PTH levels in women attending an OP program. Calcif Tissue Int 1999; 64: 275-9.

  68. Heaney RP: Bone mass, bone fragility, and the decision to threat. JAMA 1998; 280: 2119-20.

  69. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME: A metaanalysis on the use of biphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26: 1148-57

  70. Hooper M, Ebeling P, Roberts A, D’Emden M, Nicholson G, Crusan C, Wenderoth D, Ethgen D: Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int 1999; 64(Suppl 1): S69.

  71. Ho YV, Briganit EM, Duan Y, Buchanan R, Hall S, Seeman E: Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis. Osteopor Int 1999: 134-8.

  72. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1999; 280: 605-13.

  73. Iwamoto I, Kosha S, Noguchi S, Murakami M, Fujino T, Douchi T, Nagata Y: A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women, a comparative study with vitamin D3 and estrogen-progestin therapy. Maturitas 1999; 31: 161-4.

  74. Jacpues PF, Selhub J, Bostom AG, Wlson PWF, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-54.

  75. Jordan VC: Estrogen receptor as a target for the prevention of breast cancer. J Lab Clin Med 1999; 133: 408-14.

  76. Jordan VC, Morrow M: Tamoxifen, raloxifene and the prevention of breast cancer. Endocr Rev 1999; 20: 253-78.

  77. Kanis JA, McCloskey EV: Effect of calcitonin on vertebral and other fractures. Q J Med 1999; 92: 143-9.

  78. Kanis JA, McCloskey EV, Powles T, Paterson AHG, Ashley S, Spector T: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999; 79: 1179-81.

  79. Kearney CE, Beardsworth SA, Thorpe JA, Steel SA, Purdie DW: The effect of 1-15 years of estrogen implantation on bone mineral density in hysterectomized women. Calcif Tissue Int 1999; 64: S71.

  80. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ: Use of hormone replacement therapy by post-menopausal women in the United States. Ann Intern Med 1999; 130: 545-53.

  81. Khovidhunkit W, Schoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130: 431-9.

  82. Kinyamu HK, Gallagher JC, Rafferty KA, Balhorn KE: Dietary calcium and vitamin D intake in elderly and young women: Effect on serum PTH and vitamin D metabolites. Am Clin Nutr 1998; 67: 342-8.

  83. Komm BS, Bodine PVN: The ongoing saga of OP treatment. J Cell Biochem Suppl 1998; 30/31: 277-83.

  84. Komulainen M, Kroger H, Tuppurainen MT, Heikkinen A-M, Aihava E, Honkanen R, Jurvelin J, Saarikoski S: Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: A population-based 5 year randomized trial. J Clin Endocrinol Metab 1999; 84: 546-52.

  85. Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen A-M, Aihava E, Honkanen R, Saarikosk S: HRT and vitamin D in prevention of nonvertebral fractures in post-menopausal women; a 5 year randomized trial. Maturitas 1998; 31: 45-54.

  86. Kurabayashi T, Tomita M, Matsushita H, Yahata T, Honda A, Takakuwa K, Tanaka K: Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 1999; 180: 1115-20.

  87. Lane JM, Nydick: Osteoporosis. Current modes of prevention and treatment. J Am Acad Orthop Surg 1999; 7: 19-31.

  88. Lane NE, Gore LR, Cummings SR, Hochberg MC, Scott JC, Williams EN, Nevitt MC: Serum vitamin D levels and incident changes of radiographic hip osteoarthritis. Arthritis Rheum 1999; 42: 854-60.

  89. Lane NE, Haupt D, Kimmel DB, Modin G, Kinney JH: Early estrogen replacement therapy reverses the rapid loss of trabecular bone volume and prevents further deterioration of connectivity in the rat. J Bone Miner Res 1999; 14: 206-14.

  90. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J: Occult vitamin D deficiency in post-menopausal US women with acute hip fracture. JAMA 1999; 281: 1505-11.

  91. LeBoff MS, Neuberg D, Fowier K, Shapiro CL: Chemotherapy induced amenorrhea in women with breast cancer leads to marked bone loss. Bone 1998; 23(Supp 1): 621.

  92. Lim WK, Wren B, Jepson N, Roy S, Caplan G: Effect of hormone replacement therapy on left ventricular hypertrophy. Am J Cardiol 1999; 3: 1132-4.

  93. Lips P, Chapuy MC, Dawson-Hughes B, Pois HAP, Holick MF: An international comparison of serum 25-hydroxyvitamin D measurements. Osteopor Int 1999; 9: 394-7.

  94. Lucas FL, Cauley JA, Stone RA, Cummings SR, Vogt MT, Weissfeld JL, Kuiler LH: Bone mineral density and risk of breast cancer. Differences by family history of breast cancer. Am J Epidemiol 1999; 148: 22-9.

  95. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami H-O, Persson I: Breast cancer risk following long-term estrogen and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339-44.

  96. Manicourt D-H, Altman RD, Williams JM, Devogelaer J-P, Druetz-Van Egeren A, Lenz ME, Pietma D, Thomar EJ-MA: Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999; 42: 1159-67.

  97. Masahashi T, Negoro Y, Kuroki T, Asai M, Noguchi M, Nakanishi M: Biochemical markers of bone turnover during hormone replacement therapy. Intl J Gynecol Obstet 1999; 64: 163-6.

  98. McClung M, et al: Alendronate prevents post-menopausal bone loss in women without osteoporosis. Ann Intern Med 1998; 128: 253-61.

  99. Melton LJ III: Cost-effective treatment strategies for osteoporosis. Osteop Int 1999; Suppl 2: S111-S116.

  100. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.

  101. Michaelsson K, Baron JA, Johneli O, Persson I, Ljunghali S: Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Osteopor Int 1998; 8: 540-6.

  102. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axel Rod DW, Bekker PJ: A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 1999; 106: 513-20.

  103. Miller PD, et al: Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 1997; 103: 468-476.

  104. Nand SL, Wren BG, Gross BA, Heller GZ: Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate. Obstet Gynecol 1999; 93: 1009-13.

  105. Nanda K, Bastian LA, Simel DI: Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-8.

  106. Nelson H, Harris E, Cauley J, Vogt M, Bauer D, Ensrud K, Orwoil E: Osteoporosis and fractures are common in older postmenopausal women using estrogen. Bone 1999; 23(Suppl): S152.

  107. Netelenbos C: Osteoporosis: Intervention options. Maturitas 1998; 30: 235-9.

  108. Newcomb PA, Solomon C, White E: Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Threat 1999; 53: 271-7.

  109. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J, Bergman U: Low use of longterm hormone replacement therapy in Denmark. Br J Clin Pharmacol 1999; 47: 323-8.

  110. Orwoil ES, Nelson HD: Does estrogen adequately protect post-menopausal women against osteoporosis: An iconoclastic perspective. J Clin Endocrinol Metab 1999; 84: 1872-4.

  111. Parfitt AM: A structural approach to renal bone disease. J Bone Miner Res 1998; 13: 1213-20.

  112. Patel S, Pazianas M, Tobias J, Chambers TJ, Fox S, Chow J: Early effects of hormone replacement therapy on bone. Bone 1999; 24: 245-8.

  113. Peter CP, Kindt MV, Majka JA: Comparative study of potential for biphosphonates to damage gastric mucous of rats. Dig Dis Sci 1998; 43: 1009-15.

  114. Pecherstorfer M, Mirzaei S, Horn E, Keck AV. Treatment of osteoporosis with ibandronate injected intravenously every 3 months. Calcif Tissue Int 1999; 64(Supp 1): S74.

  115. Physicians guide to prevention and treatment of OP. National Osteoporosis Foundation. Washington, D.C. 1999.

  116. Pinkerton JV, Santen R: Alternatives to the use of estrogen in postmenopausal women. Endocrine Rev 1999; 20: 308-20.

  117. Pocock NA, Culton NL, Harris ND: The potential effect on hip fracture incidence of mass screening for osteoporosis. Med J Aust 1999; 170: 486-8.

  118. Pois HAP, et al: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT Study. Osteoporos Int 1999; 9(Suppl 1): 461-8.

  119. Purdie DW, Steel SA: A 5 year prospective study of BMD behaviour in HRT treated and untreated peri-menopausal women. Bone 1998; 23(Suppl): S643.

  120. Qu Q, Harkonen PL, Vaananen HK: Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999; 73: 500-7.

  121. Ravin P, Clemmsen B, Christiansen C: Biochemical markers can predict the response in bone mass during alendronate treatment in early post-menopausal women. Bone 1999; 237-44.

  122. Recker RR, Davies KM, Dowd RM, Heaney RP: The effect of lowdose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med 1999; 130: 897-904.

  123. Reginster J-Y, Deroisy R, Pirenne H, Frederick I, Dewe W, Albert A, Collette J, Zheng SX, Gosset C: High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: A plausible role of increased parathyroid hormone secretion. Osteoporos Int 1999; 9: 121-8.

  124. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin I, Menkes C-J, Nieisen K: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteop Int 1999; 9: 75-81.

  125. Reid DM: The use of risedronate in the prevention and treatment of corticosteroid-induced osteoporosis (CIO). Calcif Tissue Int 1999; 64(Suppl 1): S1-119.

  126. Resch A, Biber E, Seifert M, Resch H: Evidence that tamoxifen preserves bone density in late post-menopausal women with breast cancer. Acta Oncol 1998; 7: 661-4.

  127. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH: Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817-21.

  128. Ringe JD, Coster A, Dorst AJ, Guttmann, Fracasso C, Umbach R: Comparative treatment of moderate postmenopausal osteoporosis with intermittent cyclical etidronate or hormone replacement. Calcif Tissue Int 1999; 64: S71.

  129. Ringe JD, Kipshoven C, Coster A, Umbach R: Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: Dose-related effects on bone density and fracture rate. Osteopor Int 1999; 9: 171-8.

  130. Romagnoli E, Caravella P, Scarnecchia L, Martinez P, Minisola S: Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients. Br J Nutr 1999; 81: 133-7.

  131. Rosenson RS, Tangney CC, Mosca LJ: Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 1998; 18: 1902-5.

  132. Roux C: A review of phase III risedronate osteoporosis studies. Calcif Tissue Int 1999; 64(Suppl 1): S119.

  133. Rozenberg S, Vasquez JB, Vandromme J, Kroli M: Educating patients about the benefits and drawbacks of hormone replacement therapy. Drugs Aging 1998; 13: 33-41.

  134. Russeli RGG, Rogers MJ: Bisphosphonates. From the laboratory to the clinic and back again. Bone 1999; 5: 97-106.

  135. Saag KG, Emkey R, Schnitzer TJ: Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis. N Engl J Med 1998; 39: 292-9.

  136. Sahota O, Masud T, San P, Hosking DJ: A comparison of alendronate, cyclical alendronate, cyclical etidronate and calcitriol in the treatment of established osteoporosis. Calcif Tissue Int 1999; 64: S67.

  137. Samuels A, Perry MJ, Tobias JH: High-dose estrogen induces de novo medullary bone formation in female mice. J Bone Miner Res 1999; 14: 178-86.

  138. Santen RJ, Petroni G: Relative versus attributable risk of breast cancer from estrogen replacement therapy. J Clin Endocrinol Metab 1999; 84: 1875-81.

  139. Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH: Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem 1999; 42: 1-24.

  140. Sato Y, Kuno H, Asoh T, Honda Y, Oizumi K: Effect of immobilization on vitamin D status and bone mass in chronically hospitalized disabled stroke patients. Age Ageing 1999; 28: 265-9.

  141. Sato Y, Manabe S, Kuno H, Oizumi K: Amelioration of osteopenia and hypovitaminosis D by la, hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66: 64-8.

  142. Sato Y, Oizumi K, Kuno H, Kaji M: Effect of immobilization upon renal synthesis of 1,25 dihydroxyvitamin D in disabled elderly stroke patients. Bone 1999; 24: 271-5.

  143. Schneider HPG, Jackisch C: Potential benefits of estrogens and progestogens on breast cancer. Int J Fertil 1998; 43: 278-85.

  144. Scott J, Thompson D, Schneider DL, Quandt S, Levis S, Black D, Suryawanshi S, Yates AJ: Alendronate reduces the risk of multiple, clinical fractures: results from FIT. Calcif Tissue Int 1999; 64(Suppl 1): S82.

  145. Selby PL, Davies M, Adams JE, Mawer EB: Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14: 652-7.

  146. Shapiro D, Stephen LJ, McLelian AR, Harrison JH, Silis GJ, Brodie MJ: Bone density and antiepileptic drugs: A case-control study in older patients. Calcif Tissue Int 1999; 64: S73.

  147. Shoupe D: Androgens and bone: Clinical implications for menopausal women. Am J Obstet Gynecol 1999; 180: S329-33.

  148. Silverman SL, et al: Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Final world wide results of the “PROOF” Study. Calcif Tissue Int 1999; 64: S43.

  149. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1999; 352: 1965-9.

  150. Spencer CP, Morris EP, Rymer JM: Selective estrogen receptor modulators: Women’s panacea for the next millennium? Am J Obstet Gynecol 1999; 180: 763-70.

  151. Stepan J, Rosenova Z: Comparison of 1 70-estradiol and calcitonin in treatment of postmenopausal bone loss. J Bone Miner Res 1997; 12(Suppl. 1): S351.

  152. Stepan J, Weiss T, Hana V, Marek J: Spine BMD and heel stiffness correspond in postmenopausal osteoporosis and its treatment with estrogen, but not in Cushing’s syndrome and its treatment. Bone 1998; 23(Suppl): S523.

  153. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE: Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: A retrospective study. Osteopor Int 1999; 9: 163-70.

  154. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical in patients. N Engl J Med 1998; 338: 777-83.

  155. Thremollieres FA, Pouilles J-M, Cauneille C, Ribot C: Coronary heart disease risk factors and menopause: A study in 1,684 French women. Atherosclerosis 1999; 142: 415-23.

  156. Tsai KS, Hsu SHJ, Yang RS, Cheng WC, Chieng PU: The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women. Calcif Tissue Int 1999; 64: 384-8.

  157. Turner RT: Mice, estrogen, and postmenopausal osteoporosis. J Bone Miner Res 1999; 14: 187-191.

  158. Twis IM, Pas O, Ramp-Koopmanschap W, Hartigh JD, Vermeij P: The effects of nitrogen containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 1999; 14: 784-91.

  159. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-56.

  160. Von der Recke P, Hansen MA, Hassager C: The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106: 273-8.

  161. Wagemans AMA, Fiolet JFBM, van der Linden ES, Menheere PPCA: Osteoporosis and intellectual disability: Is there any relation? J Intellect Disabil Res 1998; 42: 370-4.

  162. Walsh BW, Spiegelman D, Morrissey M, Sacks FM: Relationship between serum estradiol levels and the increases in high density lipoprotein levels in postmenopausal women treated with oral estradiol. J Clin Endocrinol Metab 1999; 84: 985-9.

  163. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive treatments depend on bone density. Calcif Tissue Int 1999; 64(Suppl 1): S98.

  164. Wasnich RD, Ross PD, Thompson DE, Cizza G, Yates AJ: Skeletal benefits of two years of Alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteopor Int 1999; 9: 455-60.

  165. Watts N, Hangartner T, Chesnut C, Genant H, Miller P, Eriksen E, Chines A, Axelrod D, McKeever C: Risedronate treatment prevents vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 1999; 64(Suppl 1): S42.

  166. Weiderpass E, Baron JA, Adami H-O, Magnusson C, Lindgren A, Bergstrom R, Correia N, Persson I: Low potency estrogen and risk of endometrial cancer: A case-control study. Lancet 1999; 353: 1824-8.

  167. Wu AH, Pike MC, Stram DO: Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999; 91: 529-34.

  168. Ziegler R, Kasperk C: Glucocorticoid-induced osteoporosis: Prevention and treatment. Steroids 1998; 63: 344-8.

  169. Zimmerman SI, Girman CJ, Bui VC, Chandler J, Hawkes W, Martin A, Holder I, Hebel JR, Sloane PD, Magaziner J: The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999; 9: 151-7.




2020     |     www.medigraphic.com